Atnaujinkite slapukų nuostatas

El. knyga: Haploidentical Stem Cell Transplantation: An Emerging Treatment Modality

Edited by
Kitos knygos pagal šią temą:
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

This book discusses the aspects of haploidentical transplants and will shed light on the debates and questions on this burgeoning field and timely topic. Donor selection, graft failure, minimal CD34+ cell requirement, and conditioning regimens used for haploidentical transplants will be written by expert authors dealing with this type of transplants. Approximately one third of the books' chapters cover logic and basic aspects; the remaining two thirds of the book discuss clinical aspects, outcomes, and future perspectives, thus providing a comphrensive discussion of the topic. Haploidentical transplantation is extremely timely, rapidly-changing area and increasing its use will decrease the need for time-consuming, expensive, unrelated donor search. Moreover, Haploidentical Stem Cell Transplantation brings a set of clear answers to questions of feasibility, advantages over unrelated transplants, cost effectivity and outcome.. 

1 General Indications and Logic for Haploidentical SCT
1(8)
Florent Malard
Mohamad Mohty
2 Donor Selection and Cell Dose in Haploidentical SCT
9(8)
Riad El Fakih
Mutlu Arat
Mahmoud Aljurf
3 Graft Failure and Rejection in Haploidentical Stem Cell Transplantation
17(26)
Miguel Blanquer
Jose M. Moraleda
4 Toxicity of Conditioning Regimens in Haploidentical SCT
43(14)
Meltem Kurt Yuksel
Taner Demirer
5 An Overview of the Prophylaxis and Treatment of GvHD in Haploidentical SCT
57(10)
Fabio Ciceri
6 Prevention and Treatment of Infectious Complications in Haploidentical SCT
67(28)
Angela HaGler
Thomas Lehrnbecher
Peter Bader
Thomas Klingebiel
7 Graft Versus Leukemia (GvL), Graft Versus Lymphoma Effect in Haploidentic SCT
95(8)
Jakob R. Passweg
Michael Medinger
Joerg P. Halter
8 Outcome of Haploidentical SCT in Patients with Acute Leukemia
103(16)
Albert Esquirol
Jorge Sierra
9 Outcome of Haploidentical Stem Cell Transplantation in Patients with Lymphoma
119(22)
Rocio Parody
Anna Sureda
10 Applications of Haploidentical SCT in Patients with Non-malignant Diseases
141(8)
Nicolaus Kroger
11 Applications of Haploidentical SCT in Pediatric Patients
149(30)
Marco Zecca
Patrizia Comoli
12 Innovative Approaches to Increase the Success of the Haploidentical SCT
179(10)
Ulas D. Bayraktar
Stefan O. Ciurea
13 Future Perspectives for Haploidentical SCT
189
Ugur Sahin
Taner Demirer
Dr. Taner Demirer, MD, FACP, graduated from Ankara University Medical School in Turkey in 1984 and was trained in the USA through 1987-1997.  He completed his Internal Medicine residency at the Medical College of Wisconsin in 1989-1992 and hematology/oncology and bone marrow transplant fellowship at the University of Washington, Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, in 1992-1997. He was trained under Professors Don Thomas (Nobel laureate), Dean Buckner, Frederick Appelbaum and Rainer Storb in the clinical division of FHCRC.   He is a diplomate of the American Board of Internal Medicine and Board certified in Internal Medicine and Medical Oncology.  He was given the title of Fellow of American College of Physicians (FACP) by ACP in July 1996.  He has conducted many clinical studies at the FHCRC  as principal investigator or co-investigator mainly related to peripheral blood stem cell (PBSC)  mobilization and high-dosechemotherapy (HDC) as well as autologous or allogeneic stem cell transplantations (SCT) in patients with solid tumors and hematologic malignancies.  During his career he has written many papers in the respected medical journals and books in regard to PBSC mobilization kinetics, factors influencing the PBSC collection and engraftment and allogeneic as well as autologous SCT in patients with hematologic malignancies and solid tumors.  He was chairman of the EBMT Solid Tumors Working Party (STWP) in between 2001-2007. He has conducted, chaired and published studies in related to HDC in patients with solid tumors at the EBMT STWP.  He was also board member of the Federation of the European Cancer Societies (FECS) on behalf of the EBMT through 2001-2007.  He was the president of the 29th and 41st EBMT Annual Meetings which were held in Istanbul in 2003 and 2015. He has been member of the editorial board of several international journals.  Dr. Demirer is ,currently, a professor of medicine and hematology/oncology at the Ankara University Medical School in Ankara, Turkey, and a full member of the Turkish Academy of Sciences as well as the European Academy of Sciences and Arts (EASA).